ATE425987T1 - Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung - Google Patents
Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendungInfo
- Publication number
- ATE425987T1 ATE425987T1 AT00942869T AT00942869T ATE425987T1 AT E425987 T1 ATE425987 T1 AT E425987T1 AT 00942869 T AT00942869 T AT 00942869T AT 00942869 T AT00942869 T AT 00942869T AT E425987 T1 ATE425987 T1 AT E425987T1
- Authority
- AT
- Austria
- Prior art keywords
- antigen
- alzheimer
- disease
- tau
- purified
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/334,582 US20020002270A1 (en) | 1999-06-16 | 1999-06-16 | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE425987T1 true ATE425987T1 (de) | 2009-04-15 |
Family
ID=23307870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00942869T ATE425987T1 (de) | 1999-06-16 | 2000-06-16 | Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung |
Country Status (8)
Country | Link |
---|---|
US (4) | US20020002270A1 (de) |
EP (1) | EP1189937B1 (de) |
JP (1) | JP2003503314A (de) |
AT (1) | ATE425987T1 (de) |
AU (1) | AU5743500A (de) |
CA (1) | CA2386393A1 (de) |
DE (1) | DE60041818D1 (de) |
WO (1) | WO2000078807A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
CA2483635A1 (en) * | 2002-04-25 | 2003-11-06 | Alon Shalev | Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
JP2006515999A (ja) * | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | 刺激のための外科用ツール及び技法 |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
WO2005080986A1 (en) * | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
EP1723429A1 (de) * | 2004-03-08 | 2006-11-22 | The United States of America as represented by The Secretary, Department of Health and Human Services National Institutes of Health | Autoantikörperdetektion für die krebsdiagnostik |
WO2006021957A2 (en) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
AU2006222193B2 (en) * | 2005-03-05 | 2011-11-17 | AbbVie Deutschland GmbH & Co. KG | Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies |
US8021701B1 (en) * | 2005-04-13 | 2011-09-20 | Perry Stephen C | Composition to retard the onset of symptoms of alzheimer's disease |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
EP3243527B1 (de) | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunkonjugate mit einem intrazellulär spaltbaren linker |
WO2010099199A1 (en) * | 2009-02-24 | 2010-09-02 | Gibbons Winton G | Detection of complexes of tau and amyloid |
US20130022982A1 (en) | 2009-09-14 | 2013-01-24 | Kevin Ka-Wang Wang | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
EP2506881B1 (de) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
HRP20220399T1 (hr) | 2012-12-13 | 2022-05-13 | Immunomedics, Inc. | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost |
EP2878335B1 (de) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implantat und implantationssystem für nervenstimulator |
MX2016010683A (es) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2. |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
CN106999517A (zh) | 2014-10-07 | 2017-08-01 | 免疫医疗公司 | 抗体‑药物缀合物的新辅助剂用途 |
KR20220038183A (ko) | 2014-11-14 | 2022-03-25 | 바이오메리카인코포레이티드 | Ibs 민감도 테스트 구성, 장치 및 방법 |
EP3286224A4 (de) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
WO2016210108A1 (en) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
SI3316885T1 (sl) | 2015-07-01 | 2021-09-30 | Immunomedics, Inc. | Imunokonjugati protitelo-SN-38 z linkerjem CL2A |
JP6399987B2 (ja) * | 2015-09-11 | 2018-10-03 | ヤマサ醤油株式会社 | 抗β2−GPI抗体の測定法 |
CN109655620B (zh) * | 2016-03-03 | 2022-04-19 | 浙江聚康生物工程有限公司 | 能与β淀粉样蛋白结合的生物大分子及其编码DNA、β淀粉样蛋白检测试剂盒及其用途 |
EP4342497A1 (de) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antikörper mit reduzierter bindungsaffinität für antigen |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
FR2646425B1 (fr) * | 1989-04-26 | 1991-08-30 | Neosystem Sa | Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a |
US5342580A (en) | 1990-04-17 | 1994-08-30 | Alan Brenner | Apparatus and method for measuring the amount of gas adsorbed on or desorbed from a solid and reactions of a gas with a solid |
EP0600951A4 (en) * | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
ATE438716T1 (de) * | 1991-12-06 | 2009-08-15 | Max Planck Gesellschaft | Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit |
EP0796279A1 (de) * | 1994-12-23 | 1997-09-24 | Albert Einstein College Of Medicine Of Yeshiva University | Antigene, antikörper und diagnostische test für die alzheimerschen krankheit |
ATE342920T1 (de) * | 1997-08-29 | 2006-11-15 | Innogenetics Nv | Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren |
-
1999
- 1999-06-16 US US09/334,582 patent/US20020002270A1/en not_active Abandoned
-
2000
- 2000-06-16 AU AU57435/00A patent/AU5743500A/en not_active Abandoned
- 2000-06-16 JP JP2001505565A patent/JP2003503314A/ja active Pending
- 2000-06-16 DE DE60041818T patent/DE60041818D1/de not_active Expired - Fee Related
- 2000-06-16 EP EP00942869A patent/EP1189937B1/de not_active Expired - Lifetime
- 2000-06-16 AT AT00942869T patent/ATE425987T1/de not_active IP Right Cessation
- 2000-06-16 CA CA002386393A patent/CA2386393A1/en not_active Abandoned
- 2000-06-16 WO PCT/US2000/016593 patent/WO2000078807A1/en active Search and Examination
-
2001
- 2001-12-12 US US10/017,822 patent/US6864062B2/en not_active Expired - Fee Related
-
2005
- 2005-03-08 US US11/074,958 patent/US20050272094A1/en not_active Abandoned
-
2008
- 2008-04-01 US US12/060,350 patent/US20080181883A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU5743500A (en) | 2001-01-09 |
EP1189937B1 (de) | 2009-03-18 |
JP2003503314A (ja) | 2003-01-28 |
US20080181883A1 (en) | 2008-07-31 |
WO2000078807A1 (en) | 2000-12-28 |
US20050272094A1 (en) | 2005-12-08 |
EP1189937A1 (de) | 2002-03-27 |
CA2386393A1 (en) | 2000-12-28 |
DE60041818D1 (de) | 2009-04-30 |
US20030113896A1 (en) | 2003-06-19 |
US20020002270A1 (en) | 2002-01-03 |
US6864062B2 (en) | 2005-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE425987T1 (de) | Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung | |
ATE239797T1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
ATE348157T1 (de) | Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren | |
ATE286913T1 (de) | Antikörper gegen epitope mit homologie zu auto- antigenen, verfahren zur herstellung und deren verwendungen | |
ATE258379T1 (de) | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert | |
ATE297465T1 (de) | Verfahren zur herstellung von multivalenten antigenbindenden proteinen | |
ATE145007T1 (de) | Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres | |
DE69830315D1 (de) | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung | |
EP1361229A3 (de) | Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper | |
EP0794195A3 (de) | Antikörper BV10A4H2 | |
DE240975T1 (de) | Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen. | |
FI960268A (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä | |
DE59107756D1 (de) | Monoklonale Antikörper gegen Melanom | |
DE59309239D1 (de) | Verfahren zur Isolierung und Kultivierung von transformierten Zellen sowie Verwendung dieser Zellen zur Herstellung individuumsspezifischer Antikörper | |
BG102541A (en) | Diagnostics and mediators of inflammatory processes | |
DE69233366D1 (de) | Antigene, die von Polyarthritis Rheumatoide Antikörpern erkannt werden, ihre Herstellung und ihre Anwendungen | |
EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
HUP9702359A2 (hu) | Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens | |
DE3485054D1 (de) | Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung. | |
DE69127947T2 (de) | Monoklonale Antikörper gegen menschliches IgE | |
DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
DE3587681D1 (de) | Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante. | |
ATE234858T1 (de) | Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen | |
ATE285418T1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
WO1991010735A3 (fr) | Recepteur humain de la tsh. sequence codant pour ce recepteur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |